Jason Guagenti Joins Central Ohio Urology Group as Chief Operating Officer

Jason Guagenti has been named Chief Operating Officer of Central Ohio Urology Group, the region’s leading provider of comprehensive urological services, including general urology, men’s health, women’s health, cancer care, advanced cancer treatment and radiation oncology.

With more than two decades of experience managing healthcare provider organizations, Guagenti will lead the operations of Central Ohio Urology Group’s growing clinical network of 15 offices which offers more than 50 specialties and subspecialties. Facilities in the Columbus area include the Advanced Prostate Cancer Clinic and the recently announced Robotic Surgery Institute at Central Ohio Urology Surgery Center, one of the first ambulatory surgery centers in the nation to provide robotic surgery.

Corina Tracy, Chief Executive Officer of U.S. Urology Partners, the parent company of Central Ohio Urology Group, stated, “We are delighted that Jason Guagenti is bringing his extensive experience in operations and focus on patient satisfaction to Central Ohio Urology Group. His skillset and knowledge will further elevate the patient experience while enhancing the workplace environment for our talented team.”

“I am honored to join the Central Ohio Urology Group team, which is renowned in the region for its advanced level of technology and care,” said Jason Guagenti, Chief Operating Officer of Central Ohio Urology Group. “The convenient locations and compassionate, understanding staff have made the practice a valuable resource for patients who are dealing with urological issues. When you combine that with the commitment the organization has made to invest in advanced treatments and technologies and conduct world-class research, it’s no wonder that Central Ohio Urology Group is increasingly recognized as an innovative leader in the field of urology.”

To learn more about Jason Guagenti or to schedule an appointment with the Central Ohio Urology Group care team, please visit www.centralohiourology.com or call (614) 396-2684.

About Jason Guagenti

During his 20 years of healthcare industry leadership, Jason Guagenti was most recently with Riverside Radiology and Interventional Associates as practice leader for a group of more than 120 radiologists serving 35 hospital and 100 non-hospital organizations throughout Ohio and Iowa. His background includes years of experience in the OhioHealth system, most recently at OhioHealth Corporate as Senior System Director of Food and Nutrition, with responsibility for all 10 OhioHealth hospitals and many of the ancillary food and nutrition locations throughout the system.

During his tenure at OhioHealth, Guagenti was part of select group invited to participate in EXCEL, a leadership development program for rising executives. Guagenti previously served as Senior Director of Operations at Dublin Methodist Hospital and Grady Memorial Hospital where he had direct leadership responsibility for Surgical Services and Endoscopy, and indirect leadership of all of the Support Services at these two campuses. Guagenti created an Innovation Pathway for associates and physicians at both hospitals to bring forth creative ideas and develop them. He was also previously the Director of Radiology at Riverside Methodist Hospital and chaired the OhioHealth Radiation Safety and Quality Committee focused on standardizing and improving quality in radiology throughout the system. He also served on the steering committee for the Neuroscience Center addition at Riverside Methodist Hospital.

Guagenti began his career as a radiologic technologist at Riverside Methodist Hospital and held various management positions there before being promoted to Director at Grady Memorial Hospital, also part of the OhioHealth system. A graduate of The Ohio State University, Guagenti received a bachelor’s degree in Allied Medicine. Guagenti also earned a master’s degree in Business Administration from Franklin University. He is a member in the American Society of Radiology Technologists and Association for Medical Imaging Management. Guagenti is a featured speaker at national conferences on topics such as influencing people and process improvement centered on associate and patient satisfaction.

About Central Ohio Urology Group

Central Ohio Urology Group is one of the nation’s leading providers of urological services with a network of 15 offices in the region. Headquartered just outside of Columbus in Gahanna, Ohio, Central Ohio Urology Group provides comprehensive services, including general urology, men’s health, women’s health, cancer care, advanced cancer treatment and radiation oncology. Facilities in the Columbus area include an Advanced Prostate Cancer Clinic, as well as the state-of-the-art Central Ohio Urology Surgery Center that is one of the first ambulatory surgery centers in the country to offer robotic surgery. Central Ohio Urology Group’s experienced care team provides more than 50 urological specialties and subspecialties. Central Ohio Urology Group is an affiliate of U.S. Urology Partners, one of the largest independent providers of urological and related specialty services in the nation, which is backed by NMS Capital. For more information, visit www.centralohiourology.com and www.us-uro.com.

U.S. Urology Partners Names Corina Tracy as Chief Executive Officer

U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty services, today announced that Corina Tracy will assume the position of Chief Executive Officer effective January 1, 2022.

U.S. Urology Partners was formed in 2018 to support urology practices with an experienced team of healthcare executives and resources, and is backed by NMS Capital. The rapidly growing U.S. Urology Partners clinical network consists of 24 offices in Ohio and Upstate New York through partner practices Central Ohio Urology Group and Associated Medical Professionals of NY.

Corina Tracy’s background includes nearly two decades with post-acute provider Compassus, where she was integral in growing the business from 20 locations to nearly 200 locations in 30 states. Tracy joined U.S. Urology Partners in 2021 as Chief Operating Officer. Mark Cherney, who has been serving as Chief Executive Officer since the founding of U.S. Urology Partners, will remain actively involved as Executive Chairman.

Mark Cherney, Executive Chairman and Chief Executive Officer of U.S. Urology Partners, stated, “It has been both a privilege and honor to serve as the founding CEO of U.S. Urology Partners. During the past four years, we have experienced many positive changes in both our Central Ohio and Upstate New York operations. As Executive Chairman, I will primarily be involved in strategy and development with a focus in support of Corina Tracy’s vision for growth in an ever-changing urology market. I couldn’t be more pleased to support Corina as the future generation leader and innovator for years to come.”

Corina Tracy  stated, “It has been a pleasure to work with the U.S. Urology Partners team, and I look forward to fulfilling our mission of supporting urology practices in providing optimal care to their patients. The ability to share best practices and optimize operations through the involvement of a partner like U.S. Urology Partners is a tremendous advantage during this time of increasingly complex healthcare regulations, rapidly advancing technologies and heightened consumer expectations.”

During her almost 20-year tenure at Compassus, Tracy held several leadership roles, including Executive Vice President and Chief Operating Officer, and President, Hospice & Palliative Care. She most recently served as Executive Vice President, Chief Quality, Innovation and Integration Officer, leading Compassus’ focus on clinical and organizational excellence. Her efforts helped guide Compassus’ 6,000 team members who provide quality care and manage patients’ advanced illnesses in partnership with health systems and long-term care partners.

A certified hospice and palliative nurse and end-of-life nursing educator for many years, Tracy’s experience informs her leadership and unwavering focus on providing an optimal experience for patients and their families. She has served on the Board of Directors of the National Hospice and Palliative Care Organization and been a member of the Legislative Affairs Committee and Regulatory Committee. Tracy is a member of Leadership Health Care, an initiative of the Nashville Health Care Council, and the Women Business Leaders of the U.S. Health Care Industry Foundation (WBL). Tracy received her nursing degree from Scott College and holds a Bachelor of Science in Business Administration from Upper Iowa University. She was named by Nashville Medical News to Women to Watch, an honor recognizing the top women healthcare leaders in the region.

About U.S. Urology Partners

U.S. Urology Partners is one of the nation’s largest independent providers of urology and related specialty services, including general urology, surgical procedures, advanced cancer treatment and other ancillary services. Through Central Ohio Urology Group and Associated Medical Professionals of NY, the U.S. Urology Partners practice consists of a network of 24 offices throughout Ohio and Upstate New York. U.S. Urology Partners was formed to support urology practices through an experienced team of healthcare executives and resources, while serving as a platform upon which NMS Capital intends to build a leading provider of urological services through an acquisition strategy. The U.S. Urology Partners corporate office is in Nolensville, Tennessee, just outside of Nashville. For additional information about U.S. Urology Partners, please visit the company’s website at www.us-uro.com.

U.S. Urology Partners Launches Robotic Surgery Institute at Central Ohio Urology Surgery Center, Performs One of First Ambulatory Surgery Center Robotic Prostatectomies in the Nation

Industry pioneer U.S. Urology Partners has created a Robotic Surgery Institute at Central Ohio Urology Surgery Center to advance the use of robotics technology in the field of urology. The new Institute was recently the site of one of the first robotic prostatectomies in the nation to be performed at an ambulatory surgery center (ASC) and the first in Central Ohio. There are less than five ASCs in the country currently offering robotic urologic surgeries like prostatectomy. The prostate cancer patient was able to go home the same day as the robotic surgery.

U.S. Urology Partners is one of the country’s largest independent providers of urology and related specialty services and is backed by NMS Capital. Through Central Ohio Urology Group and Associated Medical Professionals of NYU.S. Urology Partners consists of a network of 24 offices throughout Ohio and Upstate New York.

Mark Cherney, Executive Chairman and CEO of U.S. Urology Partners, stated, “We are honored to report this groundbreaking advance in the field of outpatient robotic surgery and congratulate Dr. Ronney Abaza and the clinical team. We have invested in the most advanced technology available today for the Robotic Surgery Institute at Central Ohio Urology Surgery Center to ensure that we can meet the needs of patients throughout the region and the nation.”

Ronney Abaza, M.D., F.A.C.S., one of the most experienced robotic surgeons in the world and a physician at Central Ohio Urology Group, performed the surgery. Dr. Abaza said, “Allowing our patients to have their cancer surgery at an outpatient surgery center and then go home the same day removes most of the anxiety these patients feel, particularly now during the COVID crisis. Since our cancer patients can’t afford to delay their surgery until COVID dies down, we are pleased to now allow them to have their surgery at the Robotic Surgery Institute at Central Ohio Urology Surgery Center, and they are able to go home the same day and recover in the comfort and safety of their own homes.”

The expert team of robotic surgeons at the Robotic Surgery Institute at Central Ohio Urology Surgery Center has collectively performed over 10,000 robotic surgeries and includes Ronney Abaza, M.D.John K. Burgers, M.D.Benjamin J. Martin, M.D.Rashmi “Rush” I. Patel, M.D.; and E. Bradley Pewitt, M.D., Ph.D.

The Central Ohio Urology Surgery Center is pleased to offer patients the benefits of outpatient robotic surgery for robotic procedures that include, but are not limited to: prostatectomy, nephrectomy, partial nephrectomy, adrenalectomy, pyeloplasty/ureteral reconstruction and sacrocolpopexy.

The facility is located at 701 Tech Center Drive in Gahanna, Ohio, and is less than five minutes from the Columbus Airport with shuttle service and accommodations available for out-of-town patients traveling for robotic surgery.

With a clinical network of 15 officesCentral Ohio Urology Group is the region’s leading provider of comprehensive urological services, including general urology, men’s healthwomen’s health, cancer care, advanced cancer treatment and radiation oncology. Facilities in the Columbus area include an Advanced Prostate Cancer Clinic and the ambulatory surgery center. Central Ohio Urology Group’s experienced care team provides more than 50 urological specialties and subspecialties.

To learn more about the Robotic Surgery Institute at Central Ohio Urology Surgery Center, schedule an appointment, or refer a patient, please call (614) 396-2684 or (614) 796-2842. Appointments can also be requested online at www.centralohiourology.com. Visit www.us-uro.com and www.drabaza.com for additional information.

About U.S. Urology Partners

U.S. Urology Partners is one of the nation’s largest independent providers of urology and related specialty services, including general urology, surgical procedures, advanced cancer treatment and other ancillary services. Through Central Ohio Urology Group and Associated Medical Professionals of NY, the U.S. Urology Partners practice consists of a network of 24 offices throughout Ohio and Upstate New York. U.S. Urology Partners was formed to support urology practices through an experienced team of healthcare executives and resources, while serving as a platform upon which NMS Capital intends to build a leading provider of urological services through an acquisition strategy. The U.S. Urology Partners corporate offices are in Nolensville, Tennessee, and Gahanna, Ohio, just outside of Nashville and Columbus. For additional information about U.S. Urology Partners, please visit the company’s website at www.us-uro.com.

Dr. Andrew M. Ng Joins Central Ohio Urology Group

Central Ohio Urology Group is pleased to announce that Andrew M. Ng, M.D., has joined the practice. With a network of 15 officesCentral Ohio Urology Group is the region’s leading provider of comprehensive urological services, including general urology, men’s healthwomen’s health, cancer care, advanced cancer treatment and radiation oncology.

Mark Cherney, CEO of Central Ohio Urology Group and U.S. Urology Partners, stated, ““I am very excited to welcome Dr. Ng to our practice. He provides a great blend of top-notch clinical education and knowledge with a strong passion for providing community-based care. His past work with Teach for America further confirms Andrew’s dedication to the communities he serves, and that will be evident over the course of the months and years to come.”

Dr. Ng and his growing family are excited to call Columbus home. In addition to general urology, his clinical interests include BPH/enlarged prostate, laparoscopy and minimally invasive surgery, and kidney stones. After attending the University of Washington as an undergraduate, Dr. Ng received his doctorate and also completed his Urology Residency and General Surgery Internship at the Zucker School of Medicine at Hofstra/Northwell in Lake Success, New York. Dr. Ng is a native of Orange County, California.

Dr. Ng stated, “Working with patients at Central Ohio Urology Group to manage their urologic issues is an incredible privilege. My goal is to provide the best urologic care and improve my patients’ well-being. I emphasize shared decision-making and will always incorporate my patients’ unique priorities, needs and goals.”

Dr. Ng is now accepting patients and will primarily be serving them in the Worthington office at 350 W. Wilson Bridge Road, Worthington, Ohio 43085Hilliard office at 4674 Britton Parkway, Suite 1300, Hilliard, OH 43026, and Central Ohio Urology Surgery Center at 701 Tech Center Drive, Gahanna, Ohio 43230. To make an appointment or for additional information, please contact (614) 396-2684 or visit www.centralohiourology.com.

About Central Ohio Urology Group

Central Ohio Urology Group is one of the nation’s leading providers of urological services with a network of 15 offices in the region. Headquartered just outside of Columbus in Gahanna, Ohio, Central Ohio Urology Group provides comprehensive services, including general urology, men’s healthwomen’s health, cancer care, advanced cancer treatment and radiation oncology. Facilities in the Columbus area include an Advanced Prostate Cancer Clinic, as well as a state-of-the-art, urology-specific ambulatory surgery center that is one of the first in the country to offer robotic surgery. Central Ohio Urology Group’s experienced care team provides more than 50 urological specialties and subspecialties. Central Ohio Urology Group is an affiliate of U.S. Urology Partners, one of the largest independent providers of urological and related specialty services in the nation, which is backed by NMS Capital. For more information, visit www.centralohiourology.com and www.us-uro.com.

U.S. Urology Partners Names Healthcare Visionary Raoul S. Concepcion, M.D., as Chief Science Officer

Raoul S. Concepcion, M.D., F.A.C.S., has joined U.S. Urology Partners in the newly formed role of Chief Science Officer. One of the nation’s largest independent providers of urological and related specialty services, U.S. Urology Partners provides general urology, surgical procedures, advanced cancer treatment for prostate, bladder and kidney cancers, and other ancillary services.

Dr. Concepcion will lead scientific operations of the rapidly growing U.S. Urology Partners clinical network, which now includes 24 locations through partners Central Ohio Urology Group and Associated Medical Professionals of NYDr. Concepcion has decades of experience as a pioneer and clinician at the forefront of the urology industry, including serving as a founding board member and former President of LUGPA, the premier nonprofit association and advocate for independent urology practices.

Mark Cherney, Chief Executive Officer of U.S. Urology Partners, stated, “We are excited that Dr. Raoul Concepcion has joined U.S. Urology Partners as Chief Science Officer. His longstanding experience in urological clinical research programs and analytics will assist U.S. Urology Partners and its partner practices in providing optimal care for patients. Dr. Concepcion will be particularly helpful in advancing our precision medicine program, including genomics, genetic testing and counseling.”

As urology practices seek an alternative to hospital acquisition that will allow them to focus on the practice of medicine rather than business matters, they are turning to U.S. Urology Partners. Formed in 2018, U.S. Urology Partners supports urology practices through an experienced team of healthcare executives and resources and is funded by NMS Capital.

Raoul S. Concepcion, M.D., F.A.C.S., Chief Science Officer, stated, “U.S. Urology Partners is dedicated to providing state-of-the-art care for the urologic patient by providing needed operational support and attempting to standardize care across their providers. As Chief Science Officer, I will be working alongside key physicians from the member practices to establish a precision medicine cancer management model for affiliated groups that will incorporate evidence based treatment guidelines, establish a clinical genomic medicine service and build a central clinical trials initiative. The goal is to enhance patient care and advance science, which in turn provides added value to partner practices.”

He added, “Establishing a precision medicine platform will enable the team at U.S. Urology Partners and its affiliated urology groups to deliver the correct treatment to the correct patient. The past 10 years has seen the emergence of incorporating advanced cancer management into urology practices. Now, this also mandates the understanding of genetic and genomic testing to optimize care for these patients, very much akin to the standard of care associated with breast and colorectal tumors. Thus, staying current and abreast of the rapidly evolving data presents operational challenges for the busy clinician that will be supported by U.S. Urology Partners and its Medical Advisory Team, which I am proud to be a part of.“

A native of central Ohio, Dr. Concepcion has been a Clinical Assistant Professor in the Department of Urology, Vanderbilt School of Medicine. He was a General Surgery and Urology Resident from 1984 to 1989 and served as Chief Urology Resident from 1989 to 1990. Additionally, he was a research fellow in the Light Laboratories at Vanderbilt. More recently, he has completed The City of Hope Intensive Course on Cancer Risk Assessment for hereditary cancer and genomic testing. He has been in practice since 1990, with his major clinical interest being Urologic Oncology, specializing in advanced prostate and bladder cancer and lower urinary tract reconstruction, as well as the role of genomics and genetic testing in GU tumors. He is Board Certified by the American Urological Association (AUA) and is a member of that organization, as well as the Southeastern Section of the AUA, Society of Urologic Oncology, American College of Surgeons and the Nashville Surgical Society.

From a research perspective, Dr. Concepcion has been actively involved in basic science and clinical research since his days at Vanderbilt. Dr. Concepcion has been either the principal investigator (PI) or Co-PI on many clinical trials since the 1990s. The focus as of recent has been in advanced prostate cancer, as well as biomarker development. He co-founded CUSP, a urology specific clinical trials management company that specializes in site and patient accrual for the pharmaceutical and biolab industries. From an industry perspective, Dr. Concepcion serves as an advisor, consultant or speaker for many companies involved in the diagnosis and management of prostate cancer. He is developing a precision medicine comprehensive prostate cancer program for U.S. Urology Partners and affiliated groups, centered on genomic testing, pathway development, data aggregation and clinical trial work.

About U.S. Urology Partners

U.S. Urology Partners is one of the nation’s largest independent providers of urology and related specialty services, including general urology, surgical procedures, advanced cancer treatment, and other ancillary services. Through Central Ohio Urology Group and Associated Medical Professionals of NY, the U.S. Urology Partners clinical network now consists of 24 offices, including a state-of-the-art, urology-specific ambulatory surgery center that is one of the first in the country to offer robotic surgery. U.S. Urology Partners was formed to support urology practices through an experienced team of healthcare executives and resources, while serving as a platform upon which NMS Capital intends to build a leading provider of urological services through an acquisition strategy. The U.S. Urology Partners corporate offices are in Nolensville, Tennessee, and Gahanna, Ohio, just outside of Nashville and Columbus. For additional information about U.S. Urology Partners, please visit the company’s website at www.us-uro.com.

Dr. Ronney Abaza, A World Leader in Robotic Urologic and Cancer Surgery, Joins Central Ohio Urology Group

Central Ohio Urology Group is pleased to announce that Ronney Abaza, MD, FACS, one of the most experienced robotic surgeons in the world, has joined the group to continue his focus on robotic surgery for prostate, kidney and bladder cancers and other urological conditions. Dr. Abaza ranks in the top five internationally for robotic surgery volume with more than 6,000 procedures performed, as well as being the first in the world to perform several robotic procedures.

With a clinical network of 15 officesCentral Ohio Urology Group is the region’s leading provider of comprehensive urological services, including general urology, men’s healthwomen’s health, cancer care, advanced cancer treatment and radiation oncology. Facilities in the Columbus area include an Advanced Prostate Cancer Clinic, as well as a state-of-the-art, urology-specific ambulatory surgery center. Central Ohio Urology Group is an affiliate of U.S. Urology Partners, one of the largest independent providers of urological and related specialty services in the nation, which is backed by NMS Capital.

Mark Cherney, CEO of Central Ohio Urology Group and U.S. Urology Partners, stated, “We are honored that Dr. Ronney Abaza has joined the team at Central Ohio Urology Group. As an internationally recognized pioneer in robotic surgery, he will make tremendous contributions as a member of our clinical team and, most importantly, to our patients.”

Ronney Abaza, MD, FACS, said, “Having practiced in Central Ohio for nearly 15 years, I was already aware of the excellence of the urologists at Central Ohio Urology Group, but I’m most excited to join the group because of their forward-thinking vision for robotic surgery. Central Ohio Urology Group will have one of the first urology-specific ambulatory surgery centers in the country to offer patients robotic surgery. I couldn’t pass up the opportunity to help shape this program and create the best possible experience for our patients tailored just to them and what they need.”

“My practice is 99% robotic surgery for prostate, kidney, bladder and other urologic cancers, and most of the surgeries I perform are on an outpatient basis. It was Central Ohio Urology Group’s commitment to advanced technologies, and specifically an investment in a robot, that created this opportunity. Given that ambulatory surgery center operating costs are much lower than a typical hospital, we can offer a cost-effective solution. I will continue to perform robotic surgeries in area hospitals as well, but most of my patients will now be able to have their cancer surgeries without ever having to stay in a hospital and will be back home with their family around them the same day as their surgery,” added Dr. Abaza.

Dr. Abaza is now accepting patients and will primarily serve them in the Dublin and Gahanna offices. To learn more about Dr. Abaza, visit www.centralohiourology.com or www.drabaza.com. For additional information or to schedule an appointment or refer a patient to Dr. Abaza, please contact (614) 796-2842 or request an appointment at www.centralohiourology.com.

About Ronney Abaza, MD, FACS

Dr. Ronney Abaza is a world-renowned expert in robotic surgery for prostate, kidney and bladder cancers and other urologic conditions. His practice has been dedicated solely to robotic surgery since 2008, and he has performed over 6,000 robotic surgeries making him the most experienced robotic surgeon in Ohio in any specialty and one of the top five in the world.

Dr. Abaza is a pioneer in robotic surgery as the first in the world to perform robotic surgery for adrenocortical carcinoma, kidney cancer with caval thrombi, ureteroileal anastomosis revisions after cystectomy, and renal autotransplantation, among other procedures he developed and performed for the first time. He has presented his work at national and international medical meetings, including more than 200 presentations at various meetings on robotic surgery, and has won numerous awards for his research. Dr. Abaza has authored over 130 publications and book chapters in the fields of robotic surgery and urologic cancers and is editor of the only textbook dedicated to robotic kidney surgery. His work has been featured on the covers of Urology, European Urology and the Journal of Endourology.

Dr. Abaza has given hundreds of lectures on robotic surgery and serves as faculty at medical society meetings and for educational courses both in the U.S. and internationally. He has performed live robotic surgery demonstrations broadcasted to the American Urological Association (AUA) Annual Meeting, the World Congress of Endourology, European Robotic Urology Symposium, North American Robotic Urology Symposium, International Robotic Urology Symposium, and the Society of Robotic Surgery Annual Meeting, among others. He has led the development of multidisciplinary robotic surgery programs at three institutions. He was director of a robotic urologic surgery fellowship program for 10 years training new urologists in robotic surgery. He has served as a visiting professor at several academic urology departments and has welcomed over 100 surgeons from around the world into his operating room for case observations to learn his techniques. Dr. Abaza’s educational YouTube channel of surgeries he has performed for other surgeons was started only one year ago and already has thousands of views.

Dr. Abaza has served as President of the Ohio Urological Society and currently serves as the Ohio representative to the board of the North Central Section of the American Urological Association. He also serves on the editorial boards of several medical journals. Dr. Abaza has been chosen by peer nomination for the Best Doctors in America every year since 2011.

About Central Ohio Urology Group

Central Ohio Urology Group is one of the nation’s leading providers of urological services with a network of 15 offices in the region. Headquartered just outside of Columbus in Gahanna, Ohio, Central Ohio Urology Group provides comprehensive services, including general urology, men’s health, women’s health, cancer care, advanced cancer treatment and radiation oncology. Facilities in the Columbus area include an Advanced Prostate Cancer Clinic, as well as a state-of-the-art, urology-specific ambulatory surgery center that is one of the first in the country to offer robotic surgery. Central Ohio Urology Group’s experienced care team provides more than 50 urological specialties and subspecialties. Central Ohio Urology Group is an affiliate of U.S. Urology Partners, one of the largest independent providers of urological and related specialty services in the nation, which is backed by NMS Capital. For more information, visit www.centralohiourology.com and www.us-uro.com.

U.S. Urology Partners Adds David M. Albala, M.D., to Board of Directors

U.S Urology Partners announced today that David M. Albala, M.D., has joined its Board of Directors. A board certified urologist considered an authority in laparoscopic and robotic urological surgery, Dr. Albala is internationally recognized for his decades of leadership in the field of urology. His contributions include being part of the team that performed the first laparoscopic nephrectomy in humans. An educator and researcher with 160 publications in peer-reviewed journals and 6 books, Dr. Albala’s experience includes operative demonstrations in more than 30 countries in addition to serving as a White House Fellow.

U.S. Urology Partners is one of the nation’s largest independent providers of urological and related specialty services, including general urology, surgical procedures, advanced treatment options for prostate and bladder cancer, and other ancillary services. Through its operations with Central Ohio Urology Group and recently announced partnership with Associated Medical Professionals of New York, the clinical network of U.S. Urology Partners now consists of 24 locations in the Ohio and Upstate New York regions.

Mark Cherney, Chief Executive Officer of U.S. Urology Partners, stated, “We are thrilled with Dr. David Albala joining the U.S. Urology Partners board alongside Dr. Angelo DeRosalia, his partner at Associated Medical Professionals of NY. David’s expertise and knowledge of the U.S. urology marketplace will be helpful as we continue to build our presence.”

U.S. Urology Partners was formed in 2018 to support urology practices through an experienced team of healthcare executives and resources, while serving as a platform upon which the company’s investment partner, NMS Capital, intends to build a leading provider of urological services through an acquisition strategy.

Angelo R. DeRosalia, M.D., President of U.S. Urology Partners, and Chairman and Chief Executive Officer of Associated Medical Professionals of NY, said, “Dr. Albala is a great addition to the U.S. Urology Partners board. His decades of experience and wealth of knowledge will undoubtedly serve U.S. Urology Partners well as we move forward in the future.”

David M. Albala, M.D., stated, “I am looking forward to working with U.S. Urology Partners. I believe my experience in academic urology at both Loyola University and Duke University will provide a different perspective, especially on incorporating cutting edge technology in the private sector.”

Dr. David M. Albala is a board certified urologist who is fellowship-trained in endourology, laparoscopy and robotic surgery. He graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. Following this, Dr. Albala was an endourology fellow at Washington University Medical Center in St. Louis, Missouri, under the direction of Ralph V. Clayman. At Washington University, he was part of the team that performed the first laparoscopic nephrectomy in humans. He practiced at Loyola University Medical Center in Chicago and rose from the ranks of Instructor to Full Professor in Urology and Radiology in 8 years. After 10 years at Loyola, he became a tenured Professor of Surgery (Urology) at Duke University in Durham, North Carolina. At Duke, he was Co-Director of the Endourology fellowship and the Director for the Center of Minimally Invasive and Robotic Urological Surgery. He has overall 160 publications in peer-reviewed journals and has authored 3 textbooks in endourology and 3 books in general urology. He is currently the Editor-in-Chief of the Journal of Robotic Surgery and serves on the editorial board for Current Opinions in Urology, Reviews in Urology, and Urology Index and Reviews. In addition, he serves as a reviewer for 8 other surgical journals. He is currently on the Board of Directors of the Large Urology Group Practice Association (LUGPA). LUGPA is the only nonprofit urology trade association that represents over 25% of practicing urologists in the United States.

At the present time, he is Chief of Urology at Crouse Hospital in Syracuse, New York. He is considered a national and international authority in laparoscopic and robotic urological surgery and has been an active teacher in this area for over 20 years. His research and clinical interest have focused on robotic urologic surgery. In addition, other clinical interest includes minimally invasive treatments for benign prostatic hypertrophy (BPH) and the use of fibrin sealants in surgery. He has been a Visiting Professor at numerous institutions across the United States as well as overseas in countries such as India, China, Iceland, Germany, France, Japan, Brazil, Australia and Singapore. He has done operative demonstrations in over 32 countries and 23 states. He has trained 16 fellows in endourology and advanced robotic surgery.

Dr. Albala is a past White House Fellow (1995-1996), who acted as a special assistant to Federico Peña, Secretary of Transportation, on classified and unclassified public health related issues.

About U.S. Urology Partners
U.S. Urology Partners is one of the nation’s largest independent providers of urology and related specialty services, including general urology, surgical procedures, advanced treatment options for prostate and bladder cancer, and other ancillary services. Through Central Ohio Urology Group and Associated Medical Professionals of NY, the U.S. Urology Partners practice now consists of more than 50 providers across a network of 24 offices throughout Ohio and Upstate New York, including a state-of-the-art ambulatory surgery center. U.S. Urology Partners was formed to support urology practices through an experienced team of healthcare executives and resources, while serving as a platform upon which NMS Capital intends to build a leading provider of urological services through an acquisition strategy. The U.S. Urology Partners corporate offices are in Gahanna, Ohio, and Nolensville, Tennessee, just outside of Columbus and Nashville. For additional information on U.S. Urology Partners, please visit the company’s website at www.us-uro.com.

Central Ohio Urology Group Adds Dr. Kyle M. Lester

Central Ohio Urology Group is pleased to announce that Kyle M. Lester, D.O., has joined the practice. Through a network of 15 offices in the region, Central Ohio Urology Group (COUG) is one of the nation’s leading providers of comprehensive urological services, including men’s healthwomen’s healthcancer care and radiation oncology. Facilities include a urology-specific ambulatory surgery center, as well as an Advanced Prostate Cancer ClinicCentral Ohio Urology Group is an affiliate of U.S. Urology Partners, one of the nation’s largest independent providers of urological and related specialty services in the nation, which is backed by NMS Capital.

Mark Cherney, CEO of Central Ohio Urology Group and U.S. Urology Partners, stated, “I am pleased to welcome Dr. Kyle Lester to our practice. Dr. Lester’s extensive training in urologic oncology will be of great value to our team of urologic surgeons and to the level of care we provide to our patients. Dr. Lester’s urologic oncology fellowship and training provides the group with state-of-the-art and leading-edge insight into the overall spectrum of urology diagnostics and therapies.”

Dr. Lester became interested in medicine at an early age as the son of a small town general surgeon in West Virginia. He received his doctoral degree from Virginia College of Osteopathic Medicine after attending Sewanee/The University of the South as an undergraduate. His Urologic Surgery Residency and General Surgery Internship were at the Einstein Healthcare Network. Dr. Lester continued his training through a Urologic Oncology Fellowship at the Cleveland Clinic Foundation Florida.

“I am particularly interested in the oncological aspects of urology, including prostate, kidney, bladder, testicular, adrenal and upper tract cancers. I also enjoy general urology, endourology, prosthetics and kidney stones,” said Dr. Lester.

“During my fellowship, I gained unique training in laparoscopy and robotics, which allows me to optimize patient outcomes. Particularly with a cancer diagnosis, shared decision making is a centerpiece of my practice. I strive to offer the best possible care that fits the patient’s condition and circumstances. Additionally, I humbly accept the challenge a cancer diagnosis brings to the patient and their family,” added Dr. Lester.

Dr. Lester is now accepting patients and will primarily be working from the Worthington office at 350 W. Wilson Bridge Road, Worthington, Ohio 43085 and the Central Ohio Urology Surgery Center at 701 Tech Center Drive, Gahanna, Ohio 43230. To make an appointment or for additional information, please contact (614) 396-2684 or visit www.centralohiourology.com.

About Central Ohio Urology Group

Central Ohio Urology Group (COUG) is one of the nation’s leading providers of urological services with a network of 15 offices in the region. Headquartered just outside of Columbus in Gahanna, Ohio, COUG provides comprehensive services, including men’s health, women’s health, cancer care, advanced treatment options for prostate and bladder cancer, and radiation oncology. Facilities in the Columbus, Ohio, area include a state-of-the-art ambulatory surgery center, as well as an Advanced Prostate Cancer Clinic. Central Ohio Urology Group is an affiliate of U.S. Urology Partners, one of the largest independent providers of urological and related specialty services in the nation, which is backed by NMS Capital. For more information, visit www.centralohiourology.com and www.us-uro.com.

 

U.S. Urology Partners Announces Partnership with Associated Medical Professionals of New York

U.S. Urology Partners, a portfolio company of NMS Capital, announced today its strategic partnership with Associated Medical Professionals of New York, creating one of the nation’s largest independent providers of urological and other specialty services. Terms of the transaction were not disclosed.

Associated Medical Professionals is a market-leading, multi-specialty urology practice operating throughout Syracuse, New York, and the surrounding regions. U.S. Urology Partners’ operations include one of the largest urology practices in the Midwest, Central Ohio Urology Group. The combined groups will benefit from U.S. Urology Partners’ substantial investment in people, technology and services to better address patient and employee needs in the communities they serve, while being well positioned for continued growth.

“We are excited about the synergies and strengths this new partnership brings to U.S. Urology Partners,” stated Mark Cherney, Chief Executive Officer, U.S. Urology Partners. “It’s the next step in building our platform into a world-class urology services model that provides a better patient, physician and employee experience in the communities we serve. We believe that this partnership will deliver best practices and outcomes that will lead the urological industry for decades to come.”

Dr. Angelo R. DeRosalia, Chairman and Chief Executive Officer of Associated Medical Professionals, and newly appointed U.S. Urology Partners President, commented, “This exciting partnership will allow Associated Medical Professionals to remain at the forefront as a premier provider of quality, compassionate healthcare. We are looking forward to our patients experiencing the benefits offered by U.S. Urology Partners.”

Luis Gonzalez, Partner at NMS Capital, added, “The addition of Associated Medical Professionals is a transformative partnership for U.S. Urology Partners, and along with the investment in Central Ohio Urology Group, creates a clear leader in the urology space. The transaction sends a strong signal to the market that U.S. Urology Partners has a truly differentiated approach to working with urology groups, and NMS’s track-record of successfully building market-leading practices across numerous physician specialties is an equally important factor.”

U.S. Urology Partners provides extensive leadership expertise and infrastructure resources across important functional areas, including provider recruitment, payor contracting, data analytics, compliance and business development to enhance the patient, physician and employee experience.

Nexus Health Capital served as financial advisor and Katten Muchin Rosenman provided legal advice to Associated Medical Professionals. McDermott Will & Emery and Greenberg Traurig provided legal advice to NMS and U.S. Urology Partners.

About U.S. Urology Partners

U.S. Urology Partners is one of the nation’s largest independent providers of urology and other specialty services, including general urology, surgical procedures, advanced treatment options for prostate and bladder cancer, and other ancillary services. The practice now consists of more than 50 providers across a clinical network with 24 offices throughout central Ohio and upstate New York, including a state-of-the-art ambulatory surgery center. U.S. Urology Partners was formed to support urology practices through an experienced team of healthcare executives and resources, while serving as a platform upon which NMS Capital intends to build a leading provider of urological services through an acquisition strategy. U.S. Urology Partners’ corporate offices are in Gahanna, Ohio, and Nolensville, Tennessee, just outside of Columbus and Nashville. For additional information on U.S. Urology Partners, please visit the company’s website at www.us-uro.com.

About Associated Medical Professionals of New York

Associated Medical Professionals of New York (“AMP”) is a multi-specialty medical practice based in Syracuse, New York, serving the Central New York region. Established in 2008, AMP has grown to become one of the largest multi-specialty groups of its kind in the area that strives to provide quality healthcare at each of the nine locations. As a pivotal point of care in each community, AMP is able to provide continuity of care for a vast population of patients. AMP maintains a robust suite of ancillary services, including radiation oncology, pathology, lithotripsy, imaging and clinical research. AMP’s provider base consists of more than 30 providers and numerous clinical support staff practicing in nine office locations. For more information on Associated Medical Professionals, please visit the company’s website at www.ampofny.com.

About NMS Capital

NMS Capital is a New York headquartered private investment firm specializing in strategic equity investments and leveraged buyouts of lower middle market companies. The firm was formed through the spin-out of a group of portfolio companies from the Goldman Sachs Merchant Banking Division. NMS focuses on companies headquartered in the U.S. poised to benefit from sustainable growth trends with particular concentration on companies in Business Services and Healthcare Services. For additional information on NMS Capital, please visit the firm’s website at www.nms-capital.com.

Central Ohio Urology Group First in Region to Office Micro-Ultrasound for Most Accurate Prostate Cancer Diagnosis

Central Ohio Urology Group, one of the largest urology practices in Central Ohio and the Columbus MSA, has acquired ExactVu™ Micro-Ultrasound (Micro-US), specifically designed to aid in the diagnosis of prostate cancer using real-time imaging for biopsy guidance. ExactVu dramatically improves visualization of suspicious areas of the prostate with 300 percent higher resolution over standard ultrasound, and has shown to be comparable to mpMRI for detecting clinically significant prostate cancer. ExactVu’s targeted biopsies help urologists determine, with certainty, the grade and stage of cancer, when detected.

Central Ohio Urology Group (COUG) serves patients throughout Central Ohio with 21 urologists practicing at 15 locations, including a prostate cancer center and an ambulatory surgery center. COUG invests in the most advanced technologies to give patients the best possible urological care.

Adam C. Weiser, M.D., of Central Ohio Urology Group, stated, “I remember as a child the leap from black-and-white TV to color TV. Conventional ultrasound to ExactVu is the same kind of paradigm shift in visualization. We did not know what we were missing until someone showed us the difference, side by side. We hope to use the increased definition of ExactVu to cut down the number of biopsies and avoid false negatives that have plagued the previous generation of biopsy machines.”

Typically, when the urologist performs a standard ultrasound to detect prostate cancer and guide the biopsy, it is often done blind, with the possibility of results showing a false negative or under-graded cancer diagnosis.

With an imprecise diagnosis and to avoid any risk, the urologist may recommend a radical prostatectomy or radiotherapy to surgically remove or radiate the entire prostate, which may cause long-term side effects of urinary incontinence and erectile dysfunction.

Using ExactVu Micro-US, urologists can better detect smaller abnormalities and evaluate the grade and stage of the cancer. Its design also minimizes the risk of infection during biopsy through a transperineal approach.

In addition to providing comparable sensitivity to an MRI scan, ExactVu Micro-US is done in the urologist’s office. The patient does not have to travel for the MRI and return to the urologist’s office for the biopsy. Also, for some patients who are claustrophobic or have a pacemaker, an MRI may be prohibitive.

For more information about ExactVu Micro-US at Central Ohio Urology Group visit www.centralohiourology.com.